Every 10-Q that Salarius Pharmaceuticals, Inc. (SLRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SLRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SLRX filings page.
Decoy Therapeutics Inc. reported a pre-revenue first quarter with a net loss of $2.22M and cash, cash equivalents and restricted cash of $7.82M as of March 31, 2026. Research and development spending rose to $0.75M, mainly driven by the new IMP3ACT peptide conjugate program, while general and administrative costs were $1.53M.
Management states there is substantial doubt about the company’s ability to continue as a going concern, noting existing cash is only expected to fund operations into late 2026. The company plans to seek additional financing and strategic partnerships while advancing its IMP3ACT platform and legacy oncology assets SP-3164 and seclidemstat.
Salarius Pharmaceuticals (SLRX) filed its Q3 2025 10‑Q, reporting a net loss of $873,467 for the quarter and $3,540,825 for the nine months ended September 30, 2025. Operating expenses fell year over year, with research and development at $61,826 and general and administrative at $833,304 in Q3. Cash and cash equivalents were $4,809,680, and stockholders’ equity was $4,248,065.
The company disclosed substantial doubt about its ability to continue as a going concern, citing its lack of product revenue and recurring losses. Cash used in operations was $3,690,700 for the nine months, offset by $6,265,852 provided by financing activities.
Subsequent events: on November 12, 2025, Salarius closed its merger with Decoy Therapeutics and issued Series A and Series B non‑voting convertible preferred stock, together representing 4,814,106 underlying common shares subject to stockholder and Nasdaq approvals and beneficial ownership limits. The company also completed a public offering with approximately $6.3 million in net proceeds and reported 5,862,178 common shares outstanding as of November 12, 2025.
Salarius Pharmaceuticals, Inc. reported a six-month net loss of $2.67 million and a quarter-end cash balance of $794,886 as of June 30, 2025, with an accumulated deficit of $84.6 million. Operating expenses declined year-over-year driven by cost-savings actions and curtailed sponsored trials, reducing six-month R&D to $191,915 and G&A to $2.49 million. Working capital was negative and stockholders' equity was a deficit of $829,724 at June 30, 2025.
The filing discloses material liquidity and listing risks: Nasdaq notified the company of noncompliance with minimum bid-price and equity standards and a Hearings Panel granted time-limited extensions contingent on milestones. Salarius entered a merger agreement with Decoy and amended terms that materially reduce legacy Salarius ownership to 7.6% post-merger under Amendment No.2. Subsequent to quarter-end, Salarius sold shares under its ELOC for gross proceeds of approximately $3.8 million, and stockholders approved removal of the ELOC exchange cap and a possible reverse split.